Cholestatic liver disease

Medical Clinics of North America

Volumn 98, Issue 1, 2014, Pages 73-85

  Gossard, Andrea A ^a   Talwalkar, Jayant A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bile duct obstruction; Biliary tract disease; Cholestasis; Cholestatic liver disease; Primary biliary cirrhosis; Primary sclerosing cholangitis

Indexed keywords

AMOXICILLIN; ANABOLIC AGENT; ANDROGEN; AZATHIOPRINE; CAPTOPRIL; CARBAMAZEPINE; CHLORAMBUCIL; CHLORDIAZEPOXIDE; CHLORPROMAZINE; CLAVULANIC ACID; COLESTIPOL; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; DILTIAZEM; ERYTHROMYCIN; ESTROGEN; FLOXURIDINE; FLUOROURACIL; GOLD SALT; IMIPRAMINE; METHOTREXATE; NITROFURANTOIN; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; RIFAMPICIN; SILYMARIN; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

CHOLESTASIS; CHOLESTATIC LIVER DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; DYSLIPIDEMIA; FATIGUE; HUMAN; LIVER CANCER; LIVER DISEASE; LIVER DYSFUNCTION; OSTEOPOROSIS; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; REVIEW; VITAMIN DEFICIENCY; ADVERSE DRUG REACTION; BILIARY TRACT DISEASE; DIGESTIVE SYSTEM EXAMINATION; DISEASE COURSE; DISEASE MANAGEMENT; PATHOPHYSIOLOGY; AVITAMINOSIS; BILIARY TRACT DISEASES; COMPLICATION; LIVER DISEASES;

BILE DUCT OBSTRUCTION; BILIARY TRACT DISEASE; CHOLESTASIS; CHOLESTATIC LIVER DISEASE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS;

AVITAMINOSIS; BILIARY TRACT DISEASES; CHOLESTASIS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC TECHNIQUES, DIGESTIVE SYSTEM; DISEASE MANAGEMENT; DISEASE PROGRESSION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LIVER DISEASES; OSTEOPOROSIS; PRURITUS;

EID: 84888069869     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2013.09.002     Document Type: Review

References (88)

1. Heathcote E.J. Diagnosis and management of cholestatic liver disease. Clin Gastroenterol Hepatol 2007, 5(7):776-782.
2. Bennett W.F., Bova J.G. Review of hepatic imaging and a problem-oriented approach to liver masses. Hepatology 1990, 12(4 Pt 1):761-775.
3. Reddy S.I., Grace N.D. Liver imaging. A hepatologist's perspective. Clin Liver Dis 2002, 6(1):297-310. ix.
4. Saini S. Imaging of the hepatobiliary tract. NEngl J Med 1997, 336(26):1889-1894.
5. Romagnuolo J., Bardou M., Rahme E., et al. Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. Ann Intern Med 2003, 139(7):547-557.
6. Varghese J.C., Liddell R.P., Farrell M.A., et al. The diagnostic accuracy of magnetic resonance cholangiopancreatography and ultrasound compared with direct cholangiography in the detection of choledocholithiasis. Clin Radiol 1999, 54(9):604-614.
7. Freeman M.L., Nelson D.B., Sherman S., et al. Complications of endoscopic biliary sphincterotomy. NEngl J Med 1996, 335(13):909-918.
8. Mark D.H., Flamm C.R., Aronson N. Evidence-based assessment of diagnostic modalities for common bile duct stones. Gastrointest Endosc 2002, 56(Suppl 6):S190-S194.
9. Baillie J., Paulson E.K., Vitellas K.M. Biliary imaging: a review. Gastroenterology 2003, 124(6):1686-1699.
10. Heathcote E.J. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol 2002, 97(5):1090-1092.
11. Poupon R., Chazouilleres O., Corpechot C., et al. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006, 44(1):85-90.
12. Rust C., Beuers U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 2008, 14(21):3368-3373.
13. Czaja A.J. The variant forms of autoimmune hepatitis. Ann Intern Med 1996, 125(7):588-598.
14. Nakamuta M., Sakamoto S., Miyata Y., et al. Benign recurrent intrahepatic cholestasis: a long-term follow-up. Hepatogastroenterology 1994, 41(3):287-289.
15. Colombo C., Battezzati P.M., Crosignani A., et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002, 36(6):1374-1382.
16. Lindblad A., Glaumann H., Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 1999, 30(5):1151-1158.
17. Efrati O., Barak A., Modan-Moses D., et al. Liver cirrhosis and portal hypertension in cystic fibrosis. Eur J Gastroenterol Hepatol 2003, 15(10):1073-1078.
18. Colombo C., Crosignani A., Battezzati P.M. Liver involvement in cystic fibrosis. JHepatol 1999, 31(5):946-954. [review].
19. Ludwig J. Idiopathic adulthood ductopenia: an update. Mayo Clin Proc 1998, 73(3):285-291.
20. Invernizzi P., Lleo A., Podda M. Interpreting serological tests in diagnosing autoimmune liver diseases. Semin Liver Dis 2007, 27(2):161-172.
21. Maggs J.R., Chapman R.W. An update on primary sclerosing cholangitis. Curr Opin Gastroenterol 2008, 24(3):377-383.
22. Loftus E.V., Harewood G.C., Loftus C.G., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005, 54(1):91-96.
23. MacCarty R.L., LaRusso N.F., Wiesner R.H., et al. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology 1983, 149(1):39-44.
24. Bjornsson E., Olsson R., Bergquist A., et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008, 134(4):975-980.
25. Lindor K.D., Poupon R., Heathcote E.J., et al. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2000, 355(9204):657-658.
26. Corpechot C., Carrat F., Bahr A., et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005, 128(2):297-303.
27. Mitchison H.C., Palmer J.M., Bassendine M.F., et al. Acontrolled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. JHepatol 1992, 15(3):336-344.
28. Hendrickse M.T., Rigney E., Giaffer M.H., et al. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 1999, 117(2):400-407.
29. Angulo P., Patel T., Jorgensen R.A., et al. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000, 32(5):897-900.
30. Christensen E., Neuberger J., Crowe J., et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 1985, 89(5):1084-1091.
31. Hoofnagle J.H., Davis G.L., Schafer D.F., et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 1986, 91(6):1327-1334.
32. Beuers U., Spengler U., Kruis W., et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992, 16(3):707-714.
33. Stiehl A. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis. Ann Med 1994, 26(5):345-349.
34. Lindor K.D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. NEngl J Med 1997, 336(10):691-695.
35. Cullen S.N., Rust C., Fleming K., et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. JHepatol 2008, 48(5):792-800.
36. Olsson R., Boberg K.M., de Muckadell O.S., et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005, 129(5):1464-1472.
37. Lindor K.D., Kowdley K.V., Luketic V.A., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009, 50(3):808-814.
38. Imam M.H., Sinakos E., Gossard A.A., et al. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther 2011, 34(10):1185-1192.
39. Kaya M., Petersen B.T., Angulo P., et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001, 96(4):1059-1066.
40. Imam M.H., Gossard A.A., Sinakos E., et al. Pathogenesis and management of pruritus in cholestatic liver disease. JGastroenterol Hepatol 2012, 27(7):1150-1158.
41. Ghent C.N., Carruthers S.G. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988, 94(2):488-493.
42. Heathcote E.J. Is rifampin a safe and effective treatment for pruritus caused by chronic cholestasis?. Nat Clin Pract Gastroenterol Hepatol 2007, 4(4):200-201.
43. Bachs L., Pares A., Elena M., et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992, 102(6):2077-2080.
44. Podesta A., Lopez P., Terg R., et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991, 36(2):216-220.
45. Prince M.I., Burt A.D., Jones D.E. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002, 50(3):436-439.
46. Heathcote J. The pruritus of cholestasis is relieved by an opiate antagonist: is this pruritus a centrally mediated phenomenon?. Hepatology 1996, 23(5):1280-1282.
47. Bergasa N.V., Alling D.W., Talbot T.L., et al. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. JAm Acad Dermatol 1999, 41(3 Pt 1):431-434.
48. Thornton J.R., Losowsky M.S. Opioid peptides and primary biliary cirrhosis. BMJ 1988, 297(6662):1501-1504.
49. Bergasa N.V., Alling D.W., Talbot T.L., et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995, 123(3):161-167.
50. Bergasa N.V., Jones E.A. The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids. Gastroenterology 1995, 108(5):1582-1588.
51. Wolfhagen F.H., Sternieri E., Hop W.C., et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997, 113(4):1264-1269.
52. Mayo M.J., Handem I., Saldana S., et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007, 45(3):666-674.
53. Muller C., Pongratz S., Pidlich J., et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998, 10(10):865-870.
54. O'Donohue J.W., Pereira S.P., Ashdown A.C., et al. Acontrolled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther 2005, 21(8):1041-1045.
55. Witt-Sullivan H., Heathcote J., Cauch K., et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990, 12(1):98-105.
56. Cauch-Dudek K., Abbey S., Stewart D.E., et al. Fatigue in primary biliary cirrhosis. Gut 1998, 43(5):705-710.
57. Huet P.M., Deslauriers J., Tran A., et al. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol 2000, 95(3):760-767.
58. Vuoristo M., Farkkila M., Karvonen A.L., et al. Aplacebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology 1995, 108(5):1470-1478.
59. Lindor K.D., Dickson E.R., Baldus W.P., et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994, 106(5):1284-1290.
60. Heathcote E.J., Cauch-Dudek K., Walker V., et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994, 19(5):1149-1156.
61. Gross C.R., Malinchoc M., Kim W.R., et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology 1999, 29(2):356-364.
62. Katsinelos P., Vasiliadis T., Xiarchos P., et al. Ursodeoxycholic acid (UDCA) for the treatment of amoxicillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: report of two cases. Eur J Gastroenterol Hepatol 2000, 12(3):365-368.
63. Swain M.G. Fatigue in liver disease: pathophysiology and clinical management. Can J Gastroenterol 2006, 20(3):181-188.
64. Talwalkar J.A., Donlinger J.J., Gossard A.A., et al. Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. Dig Dis Sci 2006, 51(11):1985-1991.
65. Abbas G., Jorgensen R.A., Lindor K.D. Fatigue in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol 2010, 7(6):313-319.
66. Ian Gan S., de Jongh M., Kaplan M.M. Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig Dis Sci 2009, 54(10):2242-2246.
67. Swain M.G. Fatigue in chronic disease. Clin Sci (Lond) 2000, 99(1):1-8.
68. Bergasa N.V., Mehlman J.K., Jones E.A. Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000, 14(4):643-655.
69. Sokhi R.P., Anantharaju A., Kondaveeti R., et al. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl 2004, 10(5):648-653.
70. Guichelaar M.M., Malinchoc M., Sibonga J., et al. Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology 2002, 36(4 Pt 1):895-903.
71. Newton J., Francis R., Prince M., et al. Osteoporosis in primary biliary cirrhosis revisited. Gut 2001, 49(2):282-287.
72. Crippin J.S., Jorgensen R.A., Dickson E.R., et al. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994, 89(1):47-50.
73. Pereira S.P., O'Donohue J., Moniz C., et al. Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial. Aliment Pharmacol Ther 2004, 19(5):563-570.
74. Boone R.H., Cheung A.M., Girlan L.M., et al. Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci 2006, 51(6):1103-1112.
75. Guanabens N., Pares A., Ros I., et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003, 98(10):2268-2274.
76. Musialik J., Petelenz M., Gonciarz Z. Effects of alendronate on bone mass in patients with primary biliary cirrhosis and osteoporosis: preliminary results after one year. Scand J Gastroenterol 2005, 40(7):873-874.
77. Zein C.O., Jorgensen R.A., Clarke B., et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005, 42(4):762-771.
78. Phillips J.R., Angulo P., Petterson T., et al. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001, 96(9):2745-2750.
79. Jahn C.E., Schaefer E.J., Taam L.A., et al. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 1985, 89(6):1266-1278.
80. Sinakos E., Abbas G., Jorgensen R.A., et al. Serum lipids in primary sclerosing cholangitis. Dig Liver Dis 2012, 44(1):44-48.
81. Gores G.J., Wiesner R.H., Dickson E.R., et al. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology 1989, 96(6):1552-1559.
82. Jones D.E., Metcalf J.V., Collier J.D., et al. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 1997, 26(5):1138-1142.
83. Garcia-Tsao G., Sanyal A.J., Grace N.D., et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007, 46(3):922-938.
84. Bressler B., Pinto R., El-Ashry D., et al. Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection?. Gut 2005, 54(3):407-410.
85. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236.
86. Suzuki A., Lymp J., Donlinger J., et al. Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007, 5(2):259-264.
87. Imam M.H., Silveira M.G., Sinakos E., et al. Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2012, 10(2):182-185.
88. Lazaridis K.N., Gores G.J. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis 2006, 26(1):42-51.